Overview
A cross-sectional, non-interventional, observational study using qualitative patient interviews to explore patient experiences and attitudes toward taking capivasertib + fulvestrant as directed
Eligibility
Inclusion criteria (self-reported):
- Adult (over the age of 18 years)
- Diagnosed with HR+/HER2- metastatic breast cancer
- Received at least 1 week of capivasertib + fulvestrant (Patients will be invited to provide documents demonstrating the use of capivasertib. Patients will be able to participate even if unable to obtain such documentation)
Exclusion criteria (self-reported):
- Patients who had discontinued capivasertib for more than 6 months before the date of the interview
- Unable or unwilling to follow study procedures (including providing informed consent)
- Not proficient in spoken English, as assessed by the moderator
- Receiving capivasertib in a clinical trial setting
- Patients who are not able to recall instruction for administration of capivasertib in a manner consistent with the labeling (e.g. 4 days on followed by 3 days off)